1 / 17

Metabolism I

Metabolism I. PATHOPHYSIOLOGIC CLASSIFICATION OF INBORN METABOLIC DISEASES. Inborn errors of metabolism. The diseases are rare individually, but they collectively contribute significantly to mortality and morbidity (up to 1-2% of population).

amato
Télécharger la présentation

Metabolism I

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Metabolism I

  2. PATHOPHYSIOLOGIC CLASSIFICATION OFINBORN METABOLIC DISEASES

  3. Inborn errors of metabolism • The diseases are rare individually, but they collectively contribute significantly to mortality and morbidity (up to 1-2% of population). • A positive family history of unexplained child death could be obtained in most of the cases. • Early diagnosis and treatment are essential for normal long-term neurologic development. • Considerable amount of metabolic diseases could be treated effectively. • Early diagnosis requires that the possibility of metabolic disease to be considered in every sick neonate or motor-mental retarded child. • A positive family history of unexplained child death could be obtained in most of the cases.

  4. Urine and/or body odor

  5. Urine color

  6. Urine • Ferric chloride test (phenylalanine, tyrosine, homogentisic acid, • histidine, aspirin) • Ketone • Reducing substances (glucose, fructose, galactose, homogentisic acid) • Ketoacids (DNPH) • Sulfites (cyanide-nitroprusside test) • Heparan and dermatan sulphate (CTAB test) • pH, sediment (crystals), uric acid Blood • Complete blood count, glucose, blood gases • Electrolytes, ammonia, uric acid • Beta-hydroxybutyric acid, acetoacetic acid, lactic acid, pyruvic acid

  7. DIFFERENTIAL DIAGNOSIS OF NEONATAL METABOLIC DISEASES • Sepsis • Central nervous system diseases • Cardiopulmonary diseases • Perinatal asphxy (hypoxic ischemic encephalopathy) • Gastrointestinal tract obstruction

  8. Specific tests • - Amino acid chromatography (urine, serum) • - Oligosaccharide chromatography (urine, serum) • - Mucopolysaccharide electrophoresis (urine) • - Amino acids (quantitative) • - Organic acids (gas chromatography-mass spectrophotometry) • - Carnitine (plasma, urine, total, free) • - Free fatty acids, very long chained fatty acids • - Orotic acid (urine) • - Galactose-1-phosphate uridyl transferase (Beutler test) • Tissue enzymes, • DNA investigations (leukocytes, liver, fibroblasts)

  9. Central nervous system Poor suck Lethargy Irritability Hypo-or hypertonia Seizures Coma Gastrointestinal tract Poor feeding Vomiting Diarrhea Abdominal distention Cardiopulmonary system Apnea Tachypnea (compensation of metabolic acidosis) Respiratory distress Miscellaneous Abnormal skin or urine odor Cataracts Dysmorphic facies SIGNS AND SYMPTOMS OF NEONATAL METABOLIC DISEASE

  10. I. Intoxication type small diffusible molecule disease • Results from an acute or progressive intoxication from accumulation of toxic compounds proximal to the metabolic block. • Aminoacidopathies (phenylketonuria, MSUD, homocystinuria, tyrosinemia) • Organic acidopathies (pyruvic, isovaleric, methylmalonic acidemias) • Urea cycle defects (OTC deficiency, sitrullinemia etc) • Sugarintolerances (galactosemia, fructosemia etc)

  11. I. Intoxication type small diffusible molecule disease/Clinical presentation • There is a symptom free interval ranging from one day to several weeks or months. It depends on the residual enzyme activity, situations of increased catabolism (infections, stresses, operations, increased intake of proteins, stopping breast-feeding) • Clinical signs and symptoms may be early-onset acute (neonatal), late-onset acute/recurrent, or chronic progressive.

  12. Diagnosis • Diagnosis is generally easy and relies mostly on amino acid and organic acid analyses. • Treatment • Treatment requires removal of the toxins by special diets, dialysis, drug and megavitamin therapy.

  13. Energy-deficient type small diffusible molecule disease This group of diseases consists of intermediary metabolism with symptoms due at least partly to a deficiency in energy production or utilization resulting from a defect in liver myocardium, muscle or brain. • Gluconeogenesisdefects (G-6-Pase, PC, F-1, 6-diP, PEP carboxykinase) • Glycogenolysisdefects (GSD III, GSD V, and GSD VI) • Glycogenesisdefects (GSD 0, GSD IV) • Lactic acidemias (PDH deficiency, electron transport chain diseases) • Fatty acid oxidation defects(carnitine, MCAD, SCAD)

  14. Energy-deficient type small diffusible molecule disease / Clinical presentation • Hypotonia, myopathy, cardiomyopathy, failure to thrive, malformations, sudden infant death syndrome, hypoglycemia, hyperlactatemia

  15. III. Diseases that disturb the synthesis or the catabolism of complex molecules • Lysosomal diseases (Tay-Sachs, Gaucher, Neimann-Pick etc) • Peroxisomal diseases (Zellweger, Refsum, adrenolekodystrophy) • Synthesis defects (alpha-1-antitrypsin deficiency, carbohydrate deficient glycoprotein syndrome) • Clinical presentation: Chronic progressive mental-motor retardation • Diagnosis: Enzyme and DNA studies • Therapy: Enzyme therapy (İf available)

  16. Treatment-General principles 1. Removal of toxic metabolites a. Mechanical removal: (hemodialysis, peritoneal dialysis, hemofiltration and exchange transfusion). b. Diet therapy c. Drug therapy: carnitine, sodium benzoate, phenylacetic acid, NTBC 2. Addition of deficient product: glucose, arginine 3. Augmentation of residual enzyme activity(megavitamin therapy) 4. Enzyme therapy(Gaucher disease, MPS I, MPS II, MPS VI, alfa-1-antitripsin deficiency, ADA deficiency) 5. Correction of defective gene a. Organ, tissue or bone-marrow transplantation b. Somatic gene therapy (ADA deficiency)

  17. EMERGENCY TREATMENT 1. Stop protein intake 2. Interrupt catabolic state High dose energy substitution: IV 10-20 % glucose (10 mg/kg/min) (Check lactic acid and limit glucose intake when PDH deficiency suspected) b. 10-20% intralipid solutions (exclude ß-oxidation defects) 3. Ensure adequate intake of fluid (150mL/kg/day) and electrolyte (0.2% Na Cl): Aim for a sodium concentration ≥140 mEq/L to reduce the risk of cerebral edema 4. Correct acidosis: Aim for a bicarbonate concentration ≥18 mEq/L 5. Removal of toxic metabolites • Mechanical removal: (hemodialysis, peritoneal dialysis, hemofiltration and exchange transfusion). • Carnitine: 50-100 g/kg/day

More Related